Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic Malignancies
Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether febuxostat is superior to allopurinol in
the prevention of tumor lysis syndrome (TLS) in patients with hematological malignancies at
intermediate or high risk of TLS (according to Cairo-Bishop classification) who undergo
chemotherapy